CliffBio
small molecule

DAURISMO

GLASDEGIB MALEATE

Loss of exclusivityApril 2036latest FDA-listed patent expiry
CompanyPfizer →View the full company profile on CliffBio

Drug detail

Brand nameDAURISMO
Active ingredientGLASDEGIB MALEATE
StrengthEQ 25MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2018
Marketing statusRX

Listed patents

PatentExpiresType
11168066April 2036use U-3254
11891372April 2036use U-3254
10414748April 2036substance, product
8148401November 2032substance, product
8431597June 2028product

More from Pfizer

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DAURISMO patent cliff — loss of exclusivity April 2036 | CliffBio